Daniel J Daniel: Influence Statistics

Daniel J Daniel

Daniel J Daniel

Department of Psychiatry and Neurobehavioral Sciences, University of Virginia School of Medicine, Charlottesville, VA, United States | Psychiatry, University of Virginia, ...

Daniel J Daniel: Expert Impact

Concepts for which Daniel J Daniel has direct influence: Blood glucose , Type 1 diabetes , Severe hypoglycemia , Driving performance , Type 2 diabetes , Type 1 , Diabetes mellitus .

Daniel J Daniel: KOL impact

Concepts related to the work of other authors for which for which Daniel J Daniel has influence: Type 1 diabetes , Blood glucose , Glycemic control , Severe hypoglycemia , Physical activity , Diabetic patients , Impaired awareness .

KOL Resume for Daniel J Daniel

Year
2022

Department of Psychiatry and Neurobehavioral Sciences, University of Virginia School of Medicine, Charlottesville, VA, United States

2021

Psychiatry, University of Virginia, Charlottesville, Virginia, USA

2020

Psychiatry and Neurobehavioral Sciences.

University of Virginia School of Medicine, Center for Behavioral Medicine Research, Charlottesville, VA, USA

2019

University of Virginia, Charlottesville, VA, USA.

Charlottesville, VA, Newport Beach, CA, Ithaca, NY

2018

Department of Psychiatry and Neurobehavioral Sciences, Center for Behavioral Medicine Research, University of Virginia School of Medicine, PO Box 800223, 22908, Charlottesville, VA, USA

University of Virginia Health Sciences Center, Center for Behavioral Medicine Research, United States

2017

Departments of Psychiatry, Internal Medicine, and Opthalmology, University of Virginia, Charlottesville, Virginia, USA

University of Virginia School of Medicine, Charlottesville, VA

2016

Behavioral Medicine Center University of Virginia Charlottesville VA USA

From the Department of Anesthesiology (J.L.H., A.M.K., D.C.S., E.C.N.), Department of Psychiatry and Neurobehavioral Sciences (M.M.), and Department of Psychiatry and Neurobehavioral Sciences (D.J.C.), University of Virginia Health System, Charlottesville, Virginia; and Department of Anesthesiology, University of California San Francisco, San Francisco, California (J.A.T.).

2015

University of Virginia, Charlottesville, VA

2014

Department of Psychiatry & Neurobehavioral Sciences, University of Virginia Health System, Charlottesville, VA, USA

University of Virginia Health System University of Virginia

2013

Department of Psychiatry and Neurobehavioral Sciences, University of Virginia Health System

Behavioral Medicine Center, University of Virginia School of Medicine, 1300 JPA, UVA Hospital West, Barringer IV, 22908, Charlottesville, VA, USA

2012

Department of Psychiatry and Neurobehavioral Sciences, University of Virginia Health System, Charlottesville, VA, 22908, USA

2011

Health Sciences Center, University of Virginia, Charlottesville, Virginia

Charlottesville, Va.

2010

University of Virginia Health System, Box 800223, Charlottesville, VA 22908, USA.

2009

Department of Psychiatry and Neurobehavioral Sciences, Center for Behavioral Medicine Research, University of Virginia Health System, P.O. Box 801075, 22908, Charlottesville, VA, USA

University of Virginia Health System, Charlottesville, Virginia.

2008

Department of Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, Virginia.

University of Virginia Health Systems, 1 Hospital Dr, Room 4491, Barringer Wing, Box 800-223, Charlottesville, VA 22908, USA.

2007

1University of Virginia Health Sciences Center, Charlottesville, Virginia 2Eli Lilly and Company, Indianapolis, Indiana

Department of Psychiatry and Neurobehavioral Sciences, University of Virginia Health System, Charlottesville, Virginia 22908, USA.

2006

Center for Behavioral Medicine Research, Department of Psychiatric Medicine, University of Virginia, Charlottesville, Virginia.

Department of Psychiatric Medicine, University of Virginia Health System, Charlottesville, VA, USA

University of Virginia, United States

2005

Departments of Psychiatric Medicine

UNIVERSITY OF VIRGINIA HEALTH SYSTEMS

2004

From the University of Virginia, Department of Psychiatric Medicine, Charlottesville

2003

Center for the Study of Complementary and Alternative Therapies, University of Virginia Health System, Charlottesville, Va. (Galper, Taylor) The Center for Behavioral Medicine Research, University of Virginia Health System, Charlottesville, Va. (Cox)

University of Virginia Health System, Charlottesville, Virginia

2002

University of Virginia, Charlottesville, USA.

2001

University of Virginia Health System, Behavioral Medicine Center, Box 800-223, Charlottesville, VA 22908, USA

2000

University of Virginia, USA

UNIVERSITY OF VIRGINIA HEALTH SCIENCES CENTER

1999

Section of Diabetes and Metabolism, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

University of Virginia Health Sciences Center Charlottesville, VA

Prominent publications by Daniel J Daniel

KOL-Index: 14924 . OBJECTIVE: Automobile accidents are the leading cause of death among adolescents, and collisions are 2 to 4 times more likely to occur among adolescents with attention-deficit/hyperactivity disorder. Studies have demonstrated that stimulants improve driving performance. This study compared 2 long-acting stimulant medications during daytime and evening driving evaluations. METHODS: ...
Known for Oros Methylphenidate | Driving Performance | Hyperactivity Disorder | Extended Release
KOL-Index: 12968 . OBJECTIVES: This study tested the hypothesis that both trait anxiety and hypoglycemic history contribute to fear of hypoglycemia (FOH) both in adolescents with type 1 diabetes mellitus (T1DM) and in their parents, and relationships between FOH and other variables including metabolic control, symptom perception, and use of insulin pump therapy. STUDY DESIGN: Thirty-nine parent-adolescent ...
Known for Hypoglycemia Foh | Trait Anxiety | 1 Diabetes | Metabolic Control
KOL-Index: 11418 . BACKGROUND: Conventional methods describing daily glycemic variability (i.e., standard deviation and coefficient of variation) do not express risk. Low and High Blood Glucose Indices (LBGI and HBGI, respectively) and Average Daily Risk Range (ADRR) are parameters derived from self-monitored blood glucose (SMBG) data that quantify risk of glycemic excursions and temporal aspects of ...
Known for Insulin Glargine | Glycemic Variability | Lbgi Hbgi | Daily Risk
KOL-Index: 11306 . OBJECTIVES: The objectives of this study were to (1) assess accuracy of hypoglycemia detection in children with type 1 diabetes and their parents, using personal digital assistant technology to collect glucose estimates and meter readings, (2) identify demographic, clinical, and psychological predictors of individual differences in accuracy, and (3) test whether poor hypoglycemia detection ...
Known for Type 1 Diabetes | Parents Children | Field Study | Severe Hypoglycemia
KOL-Index: 11264 . OBJECTIVE: Hyperglycemia is a common event among patients with type 1 and type 2 diabetes. While the cognitive-motor slowing associated with hypoglycemia is well documented, the acute effects of hyperglycemia have not been studied extensively, despite patients' reports of negative effects. This study prospectively and objectively assessed the effects of hyperglycemia on cognitive-motor ...
Known for 2 Diabetes | Type 1 | Cognitive Performance | Effects Hyperglycemia
KOL-Index: 11038 . The optimization of metabolic control in Type 1 and Type 2 diabetes mellitus (T1DM and T2DM, respectively) [i.e., the maintenance of near-normal hemoglobin A(1c) (HbA(1c)) without increasing the risk of hypoglycemia] could be enhanced by analysis of self-monitoring blood glucose (SMBG) data assessing complementary processes: exposure to hyperglycemia and hypoglycemia. We present algorithms ...
Known for Type 2 Diabetes | Metabolic Control | Severe Hypoglycemia | Monitoring Blood
KOL-Index: 10514 . OBJECTIVE: Recent studies show the importance of controlling blood glucose variability in relationship to both reducing hypoglycemia and attenuating the risk for cardiovascular and behavioral complications due to hyperglycemia. It is therefore important to design variability measures that are equally predictive of low and high blood glucose excursions. RESEARCH DESIGN AND METHODS: We ...
Known for Blood Glucose | Hypoglycemia Hyperglycemia | Variability Measures | Type Diabetes
KOL-Index: 10382 . OBJECTIVE: To prospectively evaluate the frequency and severity of hypoglycemic episodes in IDDM subjects who declare themselves to have reduced awareness of hypoglycemia, to validate their self-designations in their natural environment, and to determine objectively the presence or absence of autonomic and neuroglycopenic symptoms associated with their low blood glucose (BG) ...
Known for Reduced Awareness | Hypoglycemic Episodes | Disease Duration | Illness Surveys
KOL-Index: 10229 . BACKGROUND: Childhood constipation is a common problem, accounting for 3% of visits to pediatric clinics and 30% of visits to pediatric gastroenterologists. Estimates of the prevalence of childhood constipation vary from 0.3% to 28% with younger children being affected most often. We were unable to find any studies that specifically examine the causes of constipation in young children. Our ...
Known for Early Childhood | Constipated Children | Constipation Parents | Toilet Training
KOL-Index: 10087 . OBJECTIVE: To evaluate the clinical/research utility of the biopsycho-behavioral model of severe hypoglycemia in differentiating patients with and without a history of severe hypoglycemia and in predicting occurrence of future severe hypoglycemia. RESEARCH DESIGN AND METHODS: A total of 93 adults with type 1 diabetes (mean age 35.8 years, duration of diabetes 16 +/- 10 years, HbA1 8.6 +/- ...
Known for Severe Hypoglycemia | Low Bg | Sh Patients | 1 Diabetes
KOL-Index: 9647 . OBJECTIVE: To determine the effect of blood glucose awareness training (BGAT) on epinephrine and symptom responses to hypoglycemia in patients with type 1 diabetes enrolled in an intensive diabetes treatment (IDT) program. RESEARCH DESIGN AND METHODS: A total of 47 subjects with uncomplicated diabetes (duration 9 +/- 3 years: HbA1c 9.0 +/- 1.2%; reference range 4-6%) enrolled in a 4-month ...
Known for Type 1 Diabetes | Blood Glucose | Awareness Training | Intensive Treatment
KOL-Index: 9524 . OBJECTIVE: To compare the clinical accuracy of two different continuous glucose sensors (CGS) during euglycemia and hypoglycemia using continuous glucose-error grid analysis (CG-EGA). RESEARCH DESIGN AND METHODS: FreeStyle Navigator (Abbott Laboratories, Alameda, CA) and MiniMed CGMS (Medtronic, Northridge, CA) CGSs were applied to the abdomens of 16 type 1 diabetic subjects (age 42 +/- 3 ...
Known for Clinical Accuracy | Continuous Glucose | Error Grid | Minimed Cgms
KOL-Index: 9156 . OBJECTIVE: The intensive treatment of diabetes to achieve strict glycemic control is a common clinical goal, but it is associated with an increased incidence of hypoglycemia. Becoming hypoglycemic while driving is a hazardous condition and may lead to a greater incidence of driving mishaps. This study investigated whether diabetes is associated with increased risk of driving mishaps and ...
Known for Driving Mishaps | Type 1 | Diabetes Increased Risk | Diabetic Drivers

Key People For Blood Glucose

Top KOLs in the world
#1
David Matthew Nathan
type 2 diabetes insulin resistance cardiovascular disease
#2
David Richard Matthews
type 2 diabetes sri lanka growth hormone
#3
K George M M Alberti
blood glucose diabetes mellitus insulin sensitivity
#4
John M Lachin
type 1 diabetes cardiovascular disease complications trial
#5
American Diabetes Association
type 2 diabetes insulin sensitivity standards medical
#6
Saul M Genuth
type 2 diabetes bari 2d cardiovascular disease

Department of Psychiatry and Neurobehavioral Sciences, University of Virginia School of Medicine, Charlottesville, VA, United States | Psychiatry, University of Virginia, Charlottesville, Virginia, USA | Psychiatry and Neurobehavioral Sciences. | Dep